Titre:
  • Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Auteur:Saura, Cristina; Hlauschek, Dominik; Oliveira, Mafalda; Zardavas, Dimitros; Jallitsch-Halper, Anita; de la Peña, Lorena; Nuciforo, Paolo Giovanni; Ballestrero, Alberto; Dubsky, Peter; Lombard, Janine J.M.; Vuylsteke, Peter; Castaneda, Carlos Altamirano; Colleoni, Marco Angelo; Santos Borges, Giuliano; Ciruelos, Eva; Fornier, Monica; Boer, Katalin; Bardia, Aditya; Wilson, Timothy Richard; Stout, Thomas T.J.; Hsu, Jerry J.Y.; Shi, Yi; Piccart-Gebhart, Martine; Gnant, Michael; Baselga, José; Azambuja, Evandro
Informations sur la publication:Lancet oncology, 20, 9, page (1226-1238)
Statut de publication:Publié, 2019-09
Sujet CREF:Cancérologie
Note générale:SCOPUS: ar.j
DecretOANoAutActif
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(19)30334-1
info:pii/S1470204519303341
info:scp/85070241760
info:pmid/31402321